X4 Pharmaceuticals Inc. Stock News

BOSTON, April 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with

BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people w

BOSTON, April 04, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people wit

BOSTON, April 01, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients

X4 Pharmaceuticals, Inc. (XFOR) CEO Paula Ragan on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

X4 Pharmaceuticals (NASDAQ: XFOR ) reported its Q4 earnings results on Thursday, March 17, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings X4 Pharmaceuticals missed estimated earnings by 82.35%, reporting … Full story available on Benzinga.com

X4 Pharmaceuticals press release (XFOR): Q4 GAAP EPS of -$1.24 misses by $0.56.Cash, Cash Equivalents & Restricted Cash of $83.1 million as of December 31, 2021.Shares +2.53% PM.

Top-line data from pivotal 4WHIM Phase 3 clinical trial in WHIM syndrome expected in 4Q22

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that it will report its financial results for the fourth quarter ended December 31, 2021, and provide an update on recent business highlights, on March 17, 2022.

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc.  (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will participate in a panel at the 42 nd Annual Cowen Healthcare Conference on Monday, March 7, 2022 and in a fireside chat at the 32 nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022.

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients w

Gainers: Organogenesis (ORGO) +24%. CytomX Therapeutics (CTMX) +13%. X4 Pharmaceuticals (XFOR) +13%